Mendus to participate in several investor and industry conferences in January

Press Release

Stockholm, Sweden, January 7, 2025

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming investor and industry conferences:

43rd Annual J.P. Morgan Healthcare Conference
San Francisco, USA, January 13-16, 2025

Mendus management team will be in San Francisco for business and investor meetings during the J.P, Morgan conference

14th Annual LifeSci Partners Corporate Access Event
San Francisco, USA, January 13-15, 2025

Mendus will take part in the LifeSci Corporate Access investor event

H.C. Wainwright & Co. during JPM 2025
San Francisco, USA, January 13-16, 2025

Mendus will attend the H.C. Wainwright conference and events during JPM

Redeye Theme: Fight Cancer
Stockholm, Sweden, January 22, 2025

Mendus CEO Erik Manting will present the company and take part in a discussion panel. For more information, please see
https://www.redeye.se/events/1052608/redeye-theme-fight-cancer-3?tab=abouttheevent

Datum 2025-01-07, kl 08:00
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!